ArticleScientific reports2018
Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide).
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.Pharmacological research · 2021Pooled it
- Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma.Journal of healthcare engineering · 2022Trial
- Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge.Journal of neuro-oncology · 2026Article
- Shining a light on brain tumors: a review of Raman spectroscopy in the operating room.Journal of biomedical optics · 2026Review
- Single Institution Retrospective Study to Determine Time to First True Progression in MGMT-Methylated Glioblastoma Patients Who Received Standard of Care.Journal of clinical medicine · 2026Article
- MGMT upregulation mediates Temozolomide resistance conferred USP5 dependency.Scientific reports · 2026Article
- From Classical to Emerging Biomarkers of Brain and Central Nervous System Tumors. An Evidence-Based Review with a Focus on Gliomas.Cellular and molecular neurobiology · 2026Review
- Comprehensive analysis of clinical, pathological, and molecular risk factors affecting the prognosis of patients with glioma.Medicine · 2025Observational
- Article
- Article
- Uncovering novel functions of NUF2 in glioblastoma and MRI-based expression prediction.Scientific reports · 2025Article
- The curse of blood-brain barrier and blood-tumor barrier in malignant brain tumor treatment.International journal of clinical oncology · 2025Review
- Association of Health Disparities with Glioblastoma Treatment and Outcomes: Insights from a 15-Year National Cohort (2005-2020).Brain sciences · 2025Article
- Sex differences in the molecular profile of adult diffuse glioma are shaped by IDH status and tumor microenvironment.Neuro-oncology · 2025Article
- Genetic and epigenetic landscape of OExploration of targeted anti-tumor therapy · 2025Review
- Role and mechanisms of exercise therapy in enhancing drug treatment for glioma: a review.Frontiers in immunology · 2025Review
- Unravelling the mosaic: Epigenetic diversity in glioblastoma.Molecular oncology · 2024Review
- MGMT protein expression is a reliable predictive biomarker for temozolomide-containing chemotherapy in osteosarcoma.Cancer science · 2024Article
- The Versatile Attributes of MGMT: Its Repair Mechanism, Crosstalk with Other DNA Repair Pathways, and Its Role in Cancer.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
O
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.